Related Experiment Video

Updated: Aug 15, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer?

Hiroshi Miyamoto¹, Edward M Messing, Chawnshang Chang

¹Department of Pathology, University of Rochester Medical Center, NY 14642, USA.

Nature Clinical Practice. Oncology

|November 3, 2005

Abstract

No abstract available in PubMed .

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Antibiogram Directed Prophylaxis for Transrectal Prostate Biopsy: An Application of Recommendations in the Setting of High Fluoroquinolone Escherichia coli Resistance.

Urology practice·2023

Improving Rates of Immediate Postoperative Intravesical Chemotherapy with Gemcitabine for Low-Grade Bladder Cancer: An Implementation Analysis.

Urology practice·2023

The androgen receptor in bladder cancer.

Nature reviews. Urology·2023

Safety, Tolerability, and Preliminary Efficacy of TAR-200 in Patients With Muscle-invasive Bladder Cancer Who Refused or Were Unfit for Curative-intent Therapy: A Phase 1 Study.

The Journal of urology·2023

Hypoxia increases RCC stem cell phenotype via altering the androgen receptor (AR)-lncTCFL5-2-YBX1-SOX2 signaling axis.

Cell & bioscience·2022

High dose androgen suppresses natural killer cytotoxicity of castration-resistant prostate cancer cells via altering AR/circFKBP5/miRNA-513a-5p/PD-L1 signals.

Cell death & disease·2022

See all related articles